Diseases meeting the eligibility criteria for lung transplant recipients
Conditions
Interventions
None listed
Sponsors
Nagoya University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Target diseases include pulmonary hypertension, idiopathic interstitial pneumonia, pulmonary emphysema, lung disorders after hematopoietic stem cell transplantation, and other diseases that meet the lung transplant recipient eligibility criteria defined by the Japanese Society of Lung and Heart-Lung Transplantation. Patients of any age and sex. Patients who visited the Departments of Thoracic Surgery or Respiratory Medicine at Nagoya University Hospital and underwent inpatient evaluation for lung transplantation at the same institution. Patients who were registered for lung transplantation at Nagoya University Hospital. Patients who underwent lung transplantation surgery at the Department of Thoracic Surgery, Nagoya University Hospital. Patients who agreed to allow access to and research use of their clinical information. Patients who were able to understand the content of this study and provided written informed consent. Patients who had previously provided broad consent for the use of biological samples and clinical data under the study entitled "Exploratory Study of Novel Disease Markers Associated with Outcomes of Chronic Interstitial Lung Diseases" (Approval No. 2017-0169).
Exclusion criteria
Exclusion criteria: Patients who are unable to adequately understand the content of the study and are therefore unable to provide written informed consent. Patients for whom it is difficult to obtain written informed consent directly from the individual. Patients who are judged by the attending physician to be inappropriate for enrollment in this study for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Longitudinal changes in lung allograft function after lung transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of chronic lung allograft dysfunction (CLAD) (incidence and time to onset), overall survival and post-transplant survival, incidence and severity of primary graft dysfunction (PGD), incidence of acute rejection, development of donor-specific anti-HLA antibodies (DSA), infectious events, and exploratory associations between clinical outcomes/prognosis and sample-derived markers, including oxidative stress markers, genetic variants, and gene (RNA) and protein expression profiles. | — |
Countries
Japan
Contacts
Public ContactTaiki Ryo
Nagoya University Graduate School of Medicine Department of Thoracic surgery
Outcome results
None listed